{
    "num_trials": 29,
    "nct_ids": [
        "NCT05579366",
        "NCT05491226",
        "NCT05107674",
        "NCT05230186",
        "NCT06299163",
        "NCT05453825",
        "NCT05848739",
        "NCT03546686",
        "NCT05852691",
        "NCT04225117",
        "NCT05585034",
        "NCT05929768",
        "NCT05252390",
        "NCT06422455",
        "NCT05318469",
        "NCT05082610",
        "NCT05888831",
        "NCT04333706",
        "NCT05812807",
        "NCT06112379",
        "NCT01042379",
        "NCT04925284",
        "NCT03504488",
        "NCT03401385",
        "NCT05629585",
        "NCT04895709",
        "NCT05989828",
        "NCT05633654",
        "NCT06353997"
    ],
    "brief_titles": [
        "PRO1184 for Advanced Solid Tumors",
        "Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation",
        "A Study of NX-1607 in Adults With Advanced Malignancies",
        "A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.",
        "NM32-2668 in Adult Patients With Selected Advanced Solid Tumors",
        "A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors",
        "A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors",
        "Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer",
        "A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer",
        "A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)",
        "Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb\u00ae808 in Combination With Pembrolizumab in Advanced Solid Tumors",
        "Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer",
        "NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors",
        "Access to Genetic Testing in Underserved Patients With Cancer",
        "Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer",
        "A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab",
        "A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors",
        "A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)",
        "Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab",
        "A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer",
        "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer",
        "Study of XB002 in Subjects With Solid Tumors (JEWEL-101)",
        "CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)",
        "First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)",
        "A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)",
        "A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors",
        "A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer",
        "Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)",
        "Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients"
    ]
}